Dosage and Administration of Intravenous Amivantamab in Combination With Lazertinib: MARIPOSA Study

IV Amivantamab + Lazertinib Dosing (28-Day Cycles)[1,2]

Premedications

Medication	Dose	Recommended Dosing Window
Antihistamine (Required at all doses)	Diphenhydramine 25 mg to 50 mg (or equivalent)	IV: 15 to 30 mins Oral: 30 to 60 mins
Antipyretic (Required at all doses)	Acetaminophen 650 mg to 1000 mg	IV: 15 to 30 mins Oral: 30 to 60 mins
Glucocorticoid (Required at initial dose [Week 1 Day 1])	Dexamethasone 20 mg (or equivalent)	IV: 45 to 60 mins
Glucocorticoid (Required at 2nd dose [Week 1 Day 2], then optional)	Dexamethasone 10 mg (or equivalent)	IV: 45 to 60 mins



When given in combination with lazertinib, administer amivantamab any time after lazertinib when given on the same day. Refer to the lazertinib prescribing information for recommended lazertinib dosage and administration information. Please refer to the amivantamab prescribing information for dosage and administration, including prophylactic anticoagulation and premedication information.

Amivantamab Infusion and Preparation[1]

IV infusion set requirements
- In-line PES filter (0.2 µm)
- PU, PBD, PVC, PP, or PE ONLY

Prime administration set with filter with 5% dextrose or 0.9% sodium chloride solution prior to amivantamab infusion

Do not infuse in the same IV line as other agents

Infusion Rates for IV Amivantamab + Lazertinib[1]

Body Weight <80 kg

Week	Dose (per 250 mL bag)	Initial Infusion Rate (mL/hr)	Subsequent Infusion Rate† (mL/hr)
Week 1 (split dose infusion)			
Week 1 Day 1	350 mg	50	75
Week 1 Day 2	700 mg	50	75
Week 2	1050 mg	85	85
Week 3	1050 mg	125	125
Week 4	1050 mg	125	125
Week 5	1050 mg	125	125
Week 6		No dose	
Week 7 and every 2 weeks thereafter	1050 mg	125	125

Body Weight ≥80 kg

Week	Dose (per 250 mL bag)	Initial Infusion Rate (mL/hr)	Subsequent Infusion Rate† (mL/hr)
Week 1 (split dose infusion)			
Week 1 Day 1	350 mg	50	75
Week 1 Day 2	1050 mg	35	50
Week 2	1400 mg	65	65
Week 3	1400 mg	85	85
Week 4	1400 mg	125	125
Week 5	1400 mg	125	125
Week 6		No dose	
Week 7 and every 2 weeks thereafter	1400 mg	125	125

Dosage Modifications for Adverse Reactions[1]

Dose Reductions‡

Amivantamab Dose	1st Reduction	2nd Reduction	3rd Reduction
1050 mg	700 mg	350 mg	DISCONTINUE amivantamab
1400 mg	1050 mg	700 mg	

hr, hour; IV, intravenous; min, minute; PBD, polybutadiene; PE, polyethylene; PES, polyethersulfone; PP, polypropylene; PU, polyurethane; PVC, polyvinyl chloride; Q2W, every 2 weeks.

*The recommended dosage of lazertinib is 240 mg orally once daily administered in combination with amivantamab with or without food. Lazertinib tablets should be swallowed whole and not crushed, split, or chewed. If a patient misses a dose of lazertinib within 12 hours, patients are instructed to take the missed dose. If more than 12 hours has passed since the dose was to be given, patients are instructed to take the next dose at its scheduled time. If vomiting occurs any time after taking lazertinib, patients are instructed to take the next dose at its next regularly scheduled time.[3] †In the absence of infusion-related reactions, increase the initial infusion rate to the subsequent infusion rate after 2 hours based on patient tolerance. Total infusion time is ~4-6 hours for Day 1 and 6-8 hours for Day 2. Subsequent infusion time is ~2 hours.[1] ‡When administering amivantamab in combination with lazertinib, if there is an adverse reaction requiring dose reduction after withholding treatment and resolution, reduce the dose of amivantamab first. Refer to the lazertinib prescribing information for information about dosage modifications for lazertinib.

1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Cho BC, et al. *N Engl J Med*. 2024 (suppl). doi:10.1056/NEJMoa2403614. 3. LAZCLUZE™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

Johnson&Johnson